1. [CASE 1 — QUESTION 1]
A 47-year-old man with a long history of heavy alcohol use is admitted with 3 weeks of progressive jaundice, anorexia, and tender hepatomegaly. Laboratory studies show a total bilirubin of 14 mg/dL, a prothrombin time prolonged 9 seconds beyond control, and an aspartate aminotransferase of 180 units/L. His calculated Maddrey discriminant function (a prognostic score derived from prothrombin time and bilirubin) is 58. He is afebrile, and there is no overt gastrointestinal bleeding. How should his disease severity be classified, and what does the discriminant function indicate about prognosis?
A) Mild alcoholic hepatitis, with low short-term mortality and no role for pharmacotherapy
B) Moderate disease for which the discriminant function has no prognostic meaning
C) Severe alcoholic hepatitis, because a discriminant function of 32 or greater identifies a 28-day mortality of roughly 35 to 45 percent and marks candidacy for corticosteroids
D) Severe disease, but the discriminant function predicts a benign course requiring no treatment
E) End-stage disease for which only transplantation, never pharmacotherapy, is appropriate
ANSWER: C
Rationale:
A Maddrey discriminant function of 32 or greater defines severe alcoholic hepatitis, identifying a 28-day mortality of approximately 35 to 45 percent without treatment and marking the patient as a potential corticosteroid candidate; a value of 58 places this patient firmly in that severe category.
Option A: Option A is incorrect because a discriminant function of 58 is far above the severity threshold and does not represent mild disease.
Option B: Option B is incorrect because the discriminant function is precisely the validated prognostic tool for this disease.
Option D: Option D is incorrect because a high discriminant function predicts high, not benign, short-term mortality.
Option E: Option E is incorrect because severe alcoholic hepatitis without contraindication has an established pharmacological therapy in corticosteroids, so transplantation is not the only option.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. Before any corticosteroid is started, the team must confirm there are no absolute contraindications. He has trace ascites on ultrasound. Which set of evaluations best represents the mandatory pre-treatment screen?
A) Blood and urine cultures, chest imaging for pneumonia, and diagnostic paracentesis to exclude spontaneous bacterial peritonitis, since active untreated infection is an absolute contraindication to steroids
B) Echocardiography and coronary angiography to assess cardiac risk
C) A fasting lipid panel and thyroid function tests
D) Genetic testing for alcohol metabolism polymorphisms
E) Empiric broad-spectrum antibiotics for all patients, with no testing required
ANSWER: A
Rationale:
Because corticosteroids substantially raise infection risk in an immune-dysregulated cirrhotic patient, the mandatory pre-treatment screen is blood and urine cultures, chest imaging for pneumonia, and diagnostic paracentesis if ascites is present to exclude spontaneous bacterial peritonitis, and active untreated infection is an absolute contraindication.
Option B: Option B is incorrect because cardiac imaging does not address the infection risk that governs steroid initiation.
Option C: Option C is incorrect because lipid and thyroid testing are not part of the pre-steroid infection screen.
Option D: Option D is incorrect because metabolic genotyping is not part of the workup that determines steroid eligibility.
Option E: Option E is incorrect because empiric antibiotics without testing neither identify nor exclude the specific infections that contraindicate steroids.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Screening is negative, and he is started on prednisolone 40 mg orally daily. On day 7, his Lille score (a model predicting corticosteroid response) is 0.55. What is the appropriate action based on this result?
A) Continue prednisolone for the full 28 days, since the score indicates a complete response
B) Increase the prednisolone dose to overcome partial response
C) Switch to intravenous methylprednisolone to improve the response
D) Extend prednisolone to 56 days to allow a delayed response
E) Discontinue prednisolone, because a Lille score of 0.45 or above defines non-response with no survival benefit from continuing and rising infection risk
ANSWER: E
Rationale:
A Lille score of 0.45 or greater at day 7 defines non-response, predicting high 6-month mortality, so continuing prednisolone confers no survival benefit while adding immunosuppression risk; the score of 0.55 mandates discontinuation.
Option A: Option A is incorrect because complete response is defined by a score below 0.16, not 0.55.
Option B: Option B is incorrect because no Lille category calls for dose escalation, which only adds risk in a non-responder.
Option C: Option C is incorrect because changing formulation does not reverse non-response, and oral prednisolone is the preferred formulation.
Option D: Option D is incorrect because extending therapy in a defined non-responder prolongs immunosuppression without expected benefit.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Prednisolone is stopped. A colleague asks whether pentoxifylline should now be started as salvage therapy, and the family asks what most determines his long-term survival. Which response is most accurate?
A) Start pentoxifylline, because it provides a mortality benefit after steroid non-response
B) Do not start pentoxifylline, because the STOPAH trial showed it has no mortality benefit; long-term survival is determined chiefly by sustained alcohol abstinence, with addiction medicine referral and transplant evaluation in refractory disease
C) Start pentoxifylline specifically to prevent hepatorenal syndrome, its proven benefit
D) Restart prednisolone at a higher dose, since pentoxifylline and steroids are interchangeable
E) No intervention affects survival at this stage, so supportive care alone is appropriate
ANSWER: B
Rationale:
The STOPAH trial showed pentoxifylline confers no mortality benefit and does not reduce hepatorenal syndrome, so it should not be started; long-term survival depends chiefly on sustained alcohol abstinence, supported by addiction medicine referral and, in refractory severe disease at experienced centers, transplant evaluation.
Option A: Option A is incorrect because pentoxifylline has no demonstrated mortality benefit as salvage.
Option C: Option C is incorrect because pentoxifylline failed to reduce hepatorenal syndrome in STOPAH.
Option D: Option D is incorrect because the patient is a defined steroid non-responder, so restarting steroids is not indicated, and the two agents are not interchangeable.
Option E: Option E is incorrect because abstinence and structured follow-up meaningfully affect survival, so nihilism is unwarranted.
5. [CASE 2 — QUESTION 1]
A 56-year-old woman with obesity, type 2 diabetes, and biopsy-proven MASH (metabolic dysfunction-associated steatohepatitis) with stage F3 fibrosis is referred for pharmacotherapy. She has a documented history of heart failure with reduced ejection fraction. Lifestyle measures have produced minimal weight loss. Considering both her liver disease and her comorbidities, which agent is the most appropriate initial choice?
A) Pioglitazone, because its insulin-sensitizing effect is ideal for her diabetes and MASH
B) High-dose vitamin E, because it is the safest option in heart failure
C) Obeticholic acid, because it treats both MASH and heart failure
D) A glucagon-like peptide-1 (GLP-1) receptor agonist such as semaglutide, because pioglitazone is contraindicated in heart failure while a GLP-1 agonist offers weight loss, glycemic control, cardiovascular benefit, and favorable MASH histological data
E) Lactulose, because it reduces hepatic inflammation in MASH
ANSWER: D
Rationale:
Pioglitazone is contraindicated in heart failure because peroxisome proliferator-activated receptor-gamma agonism causes sodium retention and fluid redistribution, so a glucagon-like peptide-1 receptor agonist such as semaglutide is the better choice, offering weight loss, glycemic control, cardiovascular benefit, and favorable MASH histological data.
Option A: Option A is incorrect because pioglitazone's heart-failure contraindication outweighs its metabolic appeal here.
Option B: Option B is incorrect because high-dose vitamin E is not preferred in heart failure and does not address her metabolic comorbidities.
Option C: Option C is incorrect because obeticholic acid treats cholestatic disease, not MASH or heart failure, and can worsen hepatic decompensation.
Option E: Option E is incorrect because lactulose treats hepatic encephalopathy and has no role in MASH.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. Over the next year her heart failure stabilizes and her fibrosis remains F3 without progression to cirrhosis; she is Child-Pugh class A. The team considers adding resmetirom. Which statement correctly frames its use in her case?
A) Resmetirom is appropriate, because it is approved for MASH with stage F2 to F3 fibrosis and she is non-cirrhotic and Child-Pugh A; it would be avoided if she were Child-Pugh B or C
B) Resmetirom is contraindicated because it is only approved for decompensated cirrhosis
C) Resmetirom requires no liver function monitoring once started
D) Resmetirom is approved only for simple steatosis, so it does not apply to her fibrosis
E) Resmetirom should replace her GLP-1 agonist because the two cannot be used in the same patient
ANSWER: A
Rationale:
Resmetirom is approved for MASH with moderate-to-severe fibrosis, stages F2 to F3, and is appropriate for this non-cirrhotic, Child-Pugh A patient; it would be avoided in Child-Pugh B or C disease where it is not approved.
Option B: Option B is incorrect because resmetirom is not approved for decompensated cirrhosis; the opposite is true.
Option C: Option C is incorrect because liver function monitoring at baseline, 3 months, and 6 months is required.
Option D: Option D is incorrect because the indication targets F2 to F3 fibrosis, not simple steatosis.
Option E: Option E is incorrect because resmetirom and a GLP-1 agonist target different mechanisms and are not mutually exclusive in the same patient.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. She is started on resmetirom. She is then diagnosed with latent tuberculosis and a clinician proposes a rifampin-based regimen. What is the most likely pharmacokinetic consequence, and the appropriate response?
A) Rifampin will raise resmetirom levels to toxic concentrations, so the resmetirom dose should be halved
B) There is no interaction, because resmetirom is not metabolized by cytochrome P450 enzymes
C) Rifampin, a strong CYP3A4 (cytochrome P450 3A4) inducer, will lower resmetirom exposure and reduce its efficacy, so the strong inducer should be avoided and an alternative sought
D) Rifampin will convert resmetirom into a more active metabolite, enhancing efficacy
E) Resmetirom will inhibit rifampin metabolism, causing rifampin toxicity
ANSWER: C
Rationale:
Resmetirom is a substrate of CYP3A4, so the strong inducer rifampin accelerates its metabolism, lowering exposure and reducing efficacy; strong CYP3A4 inducers should be avoided and an alternative approach pursued.
Option A: Option A is incorrect because an inducer lowers, not raises, substrate levels, so dose reduction is the wrong direction.
Option B: Option B is incorrect because resmetirom is in fact a CYP3A4 substrate.
Option D: Option D is incorrect because induction increases clearance rather than generating a more active metabolite.
Option E: Option E is incorrect because the interaction runs through induction of resmetirom metabolism, not resmetirom inhibiting rifampin.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. An alternative tuberculosis regimen is chosen and resmetirom is continued. She is also taking a moderate-intensity statin for hyperlipidemia. At her follow-up, her low-density lipoprotein cholesterol has fallen substantially. What is the most appropriate interpretation and action?
A) The fall indicates resmetirom failure and the drug should be stopped
B) The statin dose should be doubled to match the new lower target
C) The statin should be stopped permanently because it cannot be used with resmetirom
D) No action is needed because resmetirom has no effect on lipids
E) The low-density lipoprotein reduction is an expected pharmacodynamic effect of resmetirom, which lowers statin requirements, so the statin dose should be reassessed and likely reduced
ANSWER: E
Rationale:
Resmetirom produces a pharmacodynamic reduction in low-density lipoprotein cholesterol and triglycerides, which lowers statin requirements, so the statin should be reassessed and is often reduced after resmetirom is established.
Option A: Option A is incorrect because a falling low-density lipoprotein reflects the drug working, not failing.
Option B: Option B is incorrect because doubling the statin compounds lipid lowering unnecessarily and raises toxicity risk.
Option C: Option C is incorrect because resmetirom and statins are not mutually exclusive; the issue is dose adjustment, not prohibition.
Option D: Option D is incorrect because resmetirom does meaningfully lower lipids, so ignoring the effect is inappropriate.
9. [CASE 3 — QUESTION 1]
A 58-year-old woman presents with fatigue and pruritus and is found to have a cholestatic liver profile with positive antimitochondrial antibodies, consistent with primary biliary cholangitis (an autoimmune disease of the small intrahepatic bile ducts). She is started on first-line therapy. Which agent is first-line, and what is its principal mechanism?
A) Obeticholic acid, which blocks the farnesoid X receptor to increase bile acid synthesis
B) Ursodeoxycholic acid, a hydrophilic bile acid that competitively displaces toxic hydrophobic bile acids such as chenodeoxycholic and deoxycholic acid from the bile acid pool
C) Bezafibrate, which is the established first-line therapy that replaces ursodeoxycholic acid
D) Cholestyramine, which dissolves intrahepatic strictures
E) Rifaximin, which sterilizes the biliary tree
ANSWER: B
Rationale:
Ursodeoxycholic acid is first-line for primary biliary cholangitis; as a hydrophilic bile acid it competitively displaces toxic hydrophobic bile acids such as chenodeoxycholic and deoxycholic acid from the pool, reducing cholangiocyte injury, with added cytoprotective and immunomodulatory effects.
Option A: Option A is incorrect because obeticholic acid is a second-line farnesoid X receptor agonist that suppresses, not increases, bile acid synthesis.
Option C: Option C is incorrect because bezafibrate is a third-line option, not a first-line replacement.
Option D: Option D is incorrect because cholestyramine is a bile acid sequestrant for pruritus and does not dissolve strictures.
Option E: Option E is incorrect because rifaximin is a gut-restricted antibiotic for hepatic encephalopathy with no role in primary biliary cholangitis.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. After 12 months of ursodeoxycholic acid, her alkaline phosphatase remains 2.3 times the upper limit of normal, indicating inadequate response. She has compensated, Child-Pugh class A disease. Second-line obeticholic acid is started. What is its mechanism, and which adverse effect most often limits its dose?
A) It is a hydrophilic bile acid, and weight gain most often limits its dose
B) It activates peroxisome proliferator-activated receptor-gamma, and heart failure most often limits its dose
C) It is a thyroid hormone receptor-beta agonist, and bladder cancer most often limits its dose
D) It is a farnesoid X receptor agonist that suppresses bile acid synthesis by downregulating CYP7A1 (cholesterol 7-alpha-hydroxylase), and pruritus is the principal dose-limiting effect
E) It is a non-absorbable antibiotic, and diarrhea most often limits its dose
ANSWER: D
Rationale:
Obeticholic acid is a farnesoid X receptor agonist that suppresses bile acid synthesis by downregulating CYP7A1, the rate-limiting synthesis enzyme, and its principal dose-limiting adverse effect is pruritus, which is frequently severe enough to require dose reduction or discontinuation.
Option A: Option A is incorrect because obeticholic acid is not a bile acid and weight gain is a pioglitazone effect.
Option B: Option B is incorrect because peroxisome proliferator-activated receptor-gamma agonism and heart-failure limitation describe pioglitazone.
Option C: Option C is incorrect because thyroid hormone receptor-beta agonism describes resmetirom and bladder cancer is a pioglitazone labeling concern.
Option E: Option E is incorrect because obeticholic acid is not an antibiotic; that profile fits rifaximin.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. Obeticholic acid markedly worsens her already troublesome pruritus and is discontinued, yet her cholestatic biochemistry remains abnormal. Which third-line agent is most appropriate, and why is it especially suited to her?
A) Bezafibrate added to ursodeoxycholic acid, a peroxisome proliferator-activated receptor-alpha agonist that can produce a biochemical response and paradoxically improves pruritus
B) Re-trial of obeticholic acid at double the dose
C) High-dose ursodeoxycholic acid at 30 mg/kg/day
D) Naltrexone as a disease-modifying biochemical therapy
E) Lactulose to improve cholestatic biochemistry
ANSWER: A
Rationale:
Bezafibrate is a third-line peroxisome proliferator-activated receptor-alpha agonist that can produce a biochemical response in primary biliary cholangitis and paradoxically improves pruritus, making it especially suited to a patient intolerant of obeticholic acid because of severe itch.
Option B: Option B is incorrect because increasing obeticholic acid would worsen the pruritus that forced its discontinuation.
Option C: Option C is incorrect because high-dose ursodeoxycholic acid is not a validated strategy for inadequate responders and is harmful in cholestatic disease.
Option D: Option D is incorrect because naltrexone is a symptomatic antipruritic, not a disease-modifying biochemical therapy.
Option E: Option E is incorrect because lactulose treats hepatic encephalopathy and does not affect cholestatic biochemistry.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Earlier, while she was still on obeticholic acid, the team had noted a rising gamma-glutamyl transferase with otherwise stable synthetic function. Had she instead progressed to Child-Pugh class B cirrhosis on obeticholic acid, how should the enzyme change and the cirrhosis status be interpreted together?
A) The gamma-glutamyl transferase rise alone proves hepatotoxicity, mandating immediate transplantation
B) Neither finding matters, because obeticholic acid is safe at all cirrhosis stages
C) The gamma-glutamyl transferase rise is an expected pharmacodynamic effect and not hepatotoxicity, but progression to Child-Pugh B is decisive because obeticholic acid is contraindicated in decompensated cirrhosis due to a risk of hepatic decompensation, so it must be stopped
D) The drug should be continued at a higher dose to control disease progression
E) She should switch to high-dose ursodeoxycholic acid, which is preferred in decompensated cirrhosis
ANSWER: C
Rationale:
An isolated gamma-glutamyl transferase rise is an expected pharmacodynamic effect of obeticholic acid and does not by itself indicate hepatotoxicity, but progression to Child-Pugh class B is decisive because the drug is contraindicated in decompensated cirrhosis owing to a reported risk of hepatic decompensation, so it must be stopped.
Option A: Option A is incorrect because an expected enzyme change is not proof of hepatotoxicity and does not by itself indicate transplantation.
Option B: Option B is incorrect because obeticholic acid is specifically contraindicated in Child-Pugh B or C disease.
Option D: Option D is incorrect because increasing the dose in decompensated cirrhosis heightens decompensation risk.
Option E: Option E is incorrect because high-dose ursodeoxycholic acid is not preferred in decompensated cirrhosis and is harmful in cholestatic disease.
13. [CASE 4 — QUESTION 1]
A 36-year-old man with ulcerative colitis is found on cholangiography to have multifocal intrahepatic and extrahepatic biliary strictures, consistent with primary sclerosing cholangitis (PSC: fibro-inflammatory stricturing of the bile ducts). He asks whether a medication can halt his disease. Which statement most accurately characterizes pharmacological options in PSC?
A) Standard-dose ursodeoxycholic acid improves transplant-free survival and should be started
B) High-dose ursodeoxycholic acid at 30 mg/kg/day is the proven disease-modifying therapy
C) Obeticholic acid halts biliary fibrosis in PSC as it does in primary biliary cholangitis
D) Bezafibrate is FDA-approved as disease-modifying therapy for PSC
E) No pharmacological agent is proven to halt fibrosis or improve transplant-free survival in PSC, and high-dose ursodeoxycholic acid is actively harmful
ANSWER: E
Rationale:
Primary sclerosing cholangitis has no pharmacological agent proven to halt fibrosis or improve transplant-free survival, and high-dose ursodeoxycholic acid at 28 to 30 mg/kg/day increased adverse events in a randomized trial and is actively contraindicated.
Option A: Option A is incorrect because standard-dose ursodeoxycholic acid has not been shown to improve outcomes in PSC.
Option B: Option B is incorrect because high-dose ursodeoxycholic acid is harmful, not a proven therapy.
Option C: Option C is incorrect because obeticholic acid does not halt fibrosis in PSC.
Option D: Option D is incorrect because bezafibrate is not FDA-approved for PSC and has no proven disease-modifying role in it.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. Two years later he develops rising bilirubin, worsening pruritus, and intermittent fevers; imaging shows a new dominant extrahepatic stricture. What is the most appropriate management of this complication?
A) Start high-dose ursodeoxycholic acid to open the stricture pharmacologically
B) Refer for endoscopic retrograde cholangiopancreatography with balloon dilation or short-term stenting of the dominant stricture
C) Begin obeticholic acid to halt the stricturing process
D) Initiate pentoxifylline for its anti-fibrotic effect on the stricture
E) Observe without intervention, since strictures in PSC do not require treatment
ANSWER: B
Rationale:
A dominant stricture in primary sclerosing cholangitis causing rising bilirubin and cholangitis is managed endoscopically with balloon dilation or short-term stenting, because no pharmacological agent treats the stricture.
Option A: Option A is incorrect because high-dose ursodeoxycholic acid is contraindicated in PSC and does not open strictures.
Option C: Option C is incorrect because obeticholic acid does not halt PSC stricturing.
Option D: Option D is incorrect because pentoxifylline has no established role in PSC strictures.
Option E: Option E is incorrect because a symptomatic dominant stricture with cholangitis requires endoscopic intervention rather than observation.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. Because PSC carries elevated malignancy risk, his hepatologist outlines a surveillance plan. Which surveillance strategy is most appropriate for this patient with PSC and concurrent ulcerative colitis?
A) No surveillance is needed because effective drug therapy controls his risk
B) Annual chest radiography to screen for metastatic disease
C) Echocardiography every 6 months to monitor portal pressures
D) Annual cholangiocarcinoma surveillance with magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) and CA 19-9, plus surveillance colonoscopy for inflammatory bowel disease-associated colorectal cancer risk
E) Bone densitometry alone, since osteoporosis is the only relevant complication
ANSWER: D
Rationale:
Primary sclerosing cholangitis requires annual cholangiocarcinoma surveillance with magnetic resonance imaging/magnetic resonance cholangiopancreatography and CA 19-9, and concurrent inflammatory bowel disease warrants surveillance colonoscopy because of the elevated colorectal cancer risk.
Option A: Option A is incorrect because no drug controls PSC risk, so surveillance is essential.
Option B: Option B is incorrect because chest radiography is not the relevant cancer surveillance for PSC.
Option C: Option C is incorrect because echocardiography does not address the malignancy surveillance needs of PSC.
Option E: Option E is incorrect because, while bone health matters in cholestatic disease, it does not substitute for cholangiocarcinoma and colorectal cancer surveillance.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. Despite endoscopic management, his disease progresses over several years to end-stage liver disease with a rising MELD (Model for End-Stage Liver Disease) score. What is the only definitive treatment for end-stage PSC, and what is its general prognosis?
A) Liver transplantation, which is the only definitive treatment for end-stage PSC, with 5-year post-transplant survival exceeding 85 percent
B) Lifelong high-dose ursodeoxycholic acid, which is curative at this stage
C) Indefinite obeticholic acid, which reverses end-stage fibrosis
D) Repeated pentoxifylline courses, which restore hepatic function
E) Permanent biliary stenting, which is curative and removes the need for transplantation
ANSWER: A
Rationale:
Liver transplantation is the only definitive treatment for end-stage primary sclerosing cholangitis, with 5-year post-transplant survival exceeding 85 percent.
Option B: Option B is incorrect because high-dose ursodeoxycholic acid is harmful in PSC and is not curative.
Option C: Option C is incorrect because obeticholic acid does not reverse end-stage fibrosis in PSC.
Option D: Option D is incorrect because pentoxifylline does not restore hepatic function.
Option E: Option E is incorrect because biliary stenting palliates dominant strictures but is not curative and does not replace transplantation in end-stage disease.
17. [CASE 5 — QUESTION 1]
A 62-year-old man with known cirrhosis is brought to the emergency department confused and disoriented with asterixis, consistent with overt hepatic encephalopathy (HE: brain dysfunction from liver insufficiency and portosystemic shunting). His wife reports he took a friend's benzodiazepine for insomnia two nights ago and has had black, tarry stools. What is the single most impactful initial step in his management?
A) Start lactulose and take no further action until mental status improves
B) Administer flumazenil and discharge him once alert
C) Identify and correct the precipitants by managing the gastrointestinal bleed and stopping the benzodiazepine, since luminal blood is a large nitrogen load and benzodiazepines are potent precipitants of encephalopathy
D) Begin a systemic antibiotic as the primary treatment for encephalopathy
E) List him immediately for liver transplantation
ANSWER: C
Rationale:
Precipitant identification and correction is the single most impactful intervention in acute overt encephalopathy; here the gastrointestinal bleed, which delivers a large nitrogen load for ammonia generation, and the benzodiazepine, a potent precipitant, must both be addressed.
Option A: Option A is incorrect because starting lactulose without correcting the precipitants leaves the drivers in place.
Option B: Option B is incorrect because flumazenil is not a stand-alone cure and discharging him ignores the active bleed and underlying encephalopathy.
Option D: Option D is incorrect because a systemic antibiotic is not the primary treatment, and precipitant correction with lactulose is the foundation.
Option E: Option E is incorrect because transplant listing is not the immediate step for a reversible precipitated episode.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. The bleed is controlled and the benzodiazepine is withheld. Lactulose is started. Which statement correctly pairs the mechanism of lactulose with its appropriate dosing endpoint?
A) Lactulose is absorbed systemically and inhibits hepatic urease; titrate to serum ammonia normalization
B) Lactulose sterilizes the colon of urease-producing bacteria; titrate to a single firm stool daily
C) Lactulose chelates circulating ammonia for renal excretion; titrate to maximum tolerated dose
D) Lactulose blocks ammonia transport across the blood-brain barrier; titrate until diarrhea occurs
E) Colonic bacteria ferment lactulose to acids that convert ammonia to membrane-impermeant ammonium trapped for fecal excretion; titrate to two to three soft stools per day
ANSWER: E
Rationale:
Colonic bacteria hydrolyze lactulose to organic acids that acidify the lumen and convert ammonia to membrane-impermeant ammonium, which is trapped for fecal excretion, and the drug is titrated to two to three soft stools per day.
Option A: Option A is incorrect because lactulose is non-absorbable and acts in the gut lumen, not on hepatic urease.
Option B: Option B is incorrect because sterilizing urease-producing bacteria describes rifaximin, and a single firm stool indicates inadequate catharsis.
Option C: Option C is incorrect because lactulose does not chelate circulating ammonia, and titrating to the maximum dose risks over-purging.
Option D: Option D is incorrect because lactulose does not block blood-brain barrier transport, and driving the patient to diarrhea causes harmful fluid and electrolyte loss.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. Over the next hours he becomes progressively more obtunded, with a depressed gag reflex and inability to protect his airway. What is the most appropriate priority before continuing oral lactulose?
A) Force oral lactulose at a higher dose regardless of his airway status
B) Secure the airway with intensive care unit evaluation and endotracheal intubation for aspiration prevention, using a lactulose retention enema in the interim
C) Administer a benzodiazepine to reduce agitation and ease oral dosing
D) Withhold all therapy until he wakes spontaneously
E) Start intravenous ursodeoxycholic acid as first-line therapy
ANSWER: B
Rationale:
Grade III to IV encephalopathy with depressed consciousness and an unprotected airway requires intensive care unit evaluation and often endotracheal intubation for aspiration prevention before oral lactulose can be given safely, with a retention enema used to deliver lactulose in the interim.
Option A: Option A is incorrect because forcing oral lactulose in a patient who cannot protect the airway risks aspiration.
Option C: Option C is incorrect because benzodiazepines precipitate and worsen encephalopathy and must be avoided.
Option D: Option D is incorrect because withholding therapy abandons treatment of a life-threatening condition.
Option E: Option E is incorrect because intravenous ursodeoxycholic acid is not a therapy for hepatic encephalopathy.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. He is extubated, recovers, and is preparing for discharge after this first hospitalization for overt encephalopathy. He will continue lactulose. What additional therapy is most appropriate for secondary prophylaxis, and what is the supporting rationale?
A) Replace lactulose with rifaximin monotherapy at discharge
B) Discharge on lactulose alone, since adding any agent offers no benefit
C) Replace lactulose with a systemic antibiotic such as neomycin
D) Add rifaximin 550 mg twice daily to ongoing lactulose, because the combination is superior to either agent alone and reduced breakthrough episodes and HE-related hospitalizations in the registration trial
E) Add a standing benzodiazepine to prevent future agitation
ANSWER: D
Rationale:
After a first episode of overt encephalopathy, rifaximin 550 mg twice daily is added to ongoing lactulose for secondary prophylaxis, because the combination is superior to either agent alone and reduced breakthrough episodes and HE-related hospitalizations in the registration trial.
Option A: Option A is incorrect because rifaximin is add-on therapy, not a monotherapy replacement for lactulose.
Option B: Option B is incorrect because adding rifaximin does provide benefit over lactulose alone.
Option C: Option C is incorrect because a systemic antibiotic introduces toxicity and resistance concerns that non-absorbed rifaximin avoids, and replacing lactulose removes its benefit.
Option E: Option E is incorrect because benzodiazepines precipitate encephalopathy and have no prophylactic role.
21. [CASE 6 — QUESTION 1]
A 59-year-old woman with decompensated cirrhosis from combined alcohol-related and cholestatic liver disease is admitted with confusion. She is on aggressive loop diuretic therapy for ascites. Labs show hypokalemia and a metabolic alkalosis, and she has asterixis. Integrating the acid-base chemistry of ammonia with the precipitant framework, what is the most appropriate management priority?
A) Correct the hypokalemia and metabolic alkalosis and reduce the diuretic, because an alkaline pH shifts the equilibrium toward un-ionized, diffusible ammonia that crosses the blood-brain barrier
B) Maximize the diuretic dose to enhance ammonia excretion
C) Administer a benzodiazepine for agitation while continuing diuresis
D) Stop lactulose, since the electrolyte disturbance renders it ineffective
E) List for immediate transplantation without addressing the electrolytes
ANSWER: A
Rationale:
Hypokalemia and metabolic alkalosis are recognized precipitants of encephalopathy because an alkaline pH shifts the ammonium-ammonia equilibrium toward un-ionized, diffusible ammonia that crosses the blood-brain barrier, so correcting the potassium and alkalosis and reducing the offending diuretic addresses the driver.
Option B: Option B is incorrect because more diuresis deepens the hypokalemia and alkalosis, intensifying the precipitant.
Option C: Option C is incorrect because benzodiazepines precipitate and worsen encephalopathy.
Option D: Option D is incorrect because lactulose remains beneficial and should be continued while the electrolytes are corrected.
Option E: Option E is incorrect because the precipitating electrolyte and acid-base disturbance must be addressed rather than bypassed.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. Her electrolytes are corrected and lactulose is up-titrated, but a covering team pushes the dose hard and she now has eight watery stools daily, worsening confusion, clinical dehydration, and new hypernatremia. What is the best adjustment to her lactulose?
A) Increase lactulose further, since more stooling always lowers ammonia
B) Add a second osmotic laxative to speed transit
C) Reduce the lactulose dose to target two to three soft stools per day and correct the dehydration and hypernatremia, because over-purging causes fluid and electrolyte disturbances that themselves precipitate encephalopathy
D) Stop lactulose entirely and rely on rifaximin alone
E) Maintain the dose and restrict free water to manage the hypernatremia
ANSWER: C
Rationale:
Lactulose is titrated to two to three soft stools daily, and over-purging beyond four stools produces dehydration and hypernatremia, which are themselves precipitants of encephalopathy, so the dose should be reduced to target and the fluid and electrolyte disturbance corrected.
Option A: Option A is incorrect because more stooling is not uniformly beneficial and the over-purging is causing the deterioration.
Option B: Option B is incorrect because a second laxative worsens the over-purging and dehydration.
Option D: Option D is incorrect because stopping lactulose abandons effective therapy when the dose can simply be reduced.
Option E: Option E is incorrect because maintaining excessive purging and only restricting water does not address the volume depletion driving the hypernatremia and confusion.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. As she stabilizes, her most distressing symptom is severe cholestatic pruritus from her underlying cholestatic liver disease. Which agent is first-line for cholestatic pruritus, and what is its mechanism?
A) Naltrexone, by central opioid antagonism
B) Rifampicin, by pregnane X receptor-mediated upregulation of bile acid detoxification
C) Sertraline, by selective serotonin reuptake inhibition
D) Lactulose, by colonic acidification
E) Cholestyramine, a bile acid sequestrant that binds bile acids in the gut lumen and interrupts their enterohepatic recycling
ANSWER: E
Rationale:
Cholestyramine is the first-line agent for cholestatic pruritus; as a bile acid sequestrant it binds bile acids in the intestinal lumen and interrupts enterohepatic recycling, lowering the accumulated bile acids that drive itch.
Option A: Option A is incorrect because naltrexone is a third-line antipruritic acting through central opioid antagonism.
Option B: Option B is incorrect because rifampicin is a second-line agent acting through pregnane X receptor-mediated detoxification.
Option C: Option C is incorrect because sertraline is a fourth-line option.
Option D: Option D is incorrect because lactulose treats hepatic encephalopathy and has no role in cholestatic pruritus.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. Synthesizing her course, the team summarizes the principles that guided her management. Which statement best integrates the correct overall approach to her decompensated cirrhosis with recurrent encephalopathy?
A) Pharmacological ammonia-lowering should always precede any search for precipitants
B) Precipitant identification and correction is the highest-yield intervention in acute episodes, lactulose titrated to two to three soft stools daily with rifaximin added for secondary prophylaxis forms the pharmacological foundation, and transplant evaluation is pursued as the MELD score rises
C) Benzodiazepines are appropriate maintenance therapy to prevent agitation between episodes
D) Aggressive diuresis should be maximized continuously regardless of electrolyte status
E) High-dose ursodeoxycholic acid is the cornerstone of encephalopathy management
ANSWER: B
Rationale:
The integrated approach prioritizes precipitant identification and correction in acute episodes, uses lactulose titrated to two to three soft stools daily with rifaximin added for secondary prophylaxis as the pharmacological foundation, and pursues transplant evaluation as the MELD score rises.
Option A: Option A is incorrect because precipitant correction is the highest-yield step and should not be deferred behind pharmacotherapy alone.
Option C: Option C is incorrect because benzodiazepines precipitate encephalopathy and are not maintenance therapy.
Option D: Option D is incorrect because unchecked diuresis causes the electrolyte and acid-base disturbances that precipitate encephalopathy.
Option E: Option E is incorrect because high-dose ursodeoxycholic acid is not a treatment for encephalopathy and is harmful in cholestatic disease.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.